PROF
Profound Medical Corp
$
6.070
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.200
Open
6.180
VWAP
6.09
Vol
27.34K
Mkt Cap
216.93M
Low
5.9412
Amount
166.58K
EV/EBITDA(TTM)
--
Total Shares
24.43M
EV
149.79M
EV/OCF(TTM)
--
P/S(TTM)
13.91
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
5.07M
+78.93%
-0.376
-1.05%
7.07M
+70.04%
-0.338
+69%
6.90M
+163.65%
-0.343
-4.86%
Estimates Revision
The market is revising Downward the revenue expectations for Profound Medical Corp. (PROF) for FY2025, with the revenue forecasts being adjusted by -6.3% over the past three months. During the same period, the stock price has changed by 6.67%.
Revenue Estimates for FY2025
Revise Downward
-6.3%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+10.14%
In Past 3 Month
Stock Price
Go Up
+6.67%
In Past 3 Month
2 Analyst Rating
Wall Street analysts forecast PROF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PROF is 11.00 USD with a low forecast of 11.00 USD and a high forecast of 11.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.070
Low
11.00
Averages
11.00
High
11.00
Current: 6.070
Low
11.00
Averages
11.00
High
11.00
Raymond James
Michael Freeman
Strong Buy
to
Outperform
downgrade
$17 -> $11
2025-05-09
Reason
Raymond James
Michael Freeman
Price Target
$17 -> $11
2025-05-09
downgrade
Strong Buy
to
Outperform
Reason
Lake Street
Benjamin Haynor
Strong Buy
Maintains
$17 → $11
2025-04-23
Reason
Lake Street
Benjamin Haynor
Price Target
$17 → $11
2025-04-23
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Profound Medical Corp (PROF.O) is -4.51, compared to its 5-year average forward P/E of -8.48. For a more detailed relative valuation and DCF analysis to assess Profound Medical Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-8.48
Current PE
-4.51
Overvalued PE
-4.06
Undervalued PE
-12.91
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-7.89
Current EV/EBITDA
-4.74
Overvalued EV/EBITDA
-3.01
Undervalued EV/EBITDA
-12.77
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Undervalued
5Y Average PS
18.22
Current PS
6.07
Overvalued PS
28.63
Undervalued PS
7.81
Financials
Annual
Quarterly
FY2025Q2
YoY :
-0.99%
2.21M
Total Revenue
FY2025Q2
YoY :
+76.05%
-13.81M
Operating Profit
FY2025Q2
-15.70M
Net Income after Tax
FY2025Q2
YoY :
+85.71%
-0.52
EPS - Diluted
FY2025Q2
N/A
Free Cash Flow
FY2025Q2
YoY :
+14.99%
73.18
Gross Profit Margin - %
FY2025Q2
N/A
FCF Margin - %
FY2025Q2
-709.86
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
100.2K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
100.2K
USD
Months
0-12
0
0.0
USD
Months
PROF News & Events
Events Timeline
2025-10-16 (ET)
2025-10-16
08:10:40
Profound Medical reveals Busch Center has successfully performed its 500th TULSA procedure.
2025-10-07 (ET)
2025-10-07
07:49:53
Profound Medical Reports Q3 Revenue of $5.2M-$5.3M, Up from $2.8M Last Year
2025-09-23 (ET)
2025-09-23
08:17:38
Profound Medical unveils TULSA in partnership with Texas Prostate and Dallas Medical
Sign Up For More Events
Sign Up For More Events
News
3.0
10-07NASDAQ.COMProfound Medical Reports Significant Q3 Preliminary Revenue Growth, Yet Falls Short of Expectations
7.5
10-07NewsfilterProfound Medical Reports Record Preliminary Unaudited Revenue for Q3 2025
5.0
09-23SeekingAlphaProfound Medical Gains Momentum with Launch of TULSA Procedure at Dallas Medical Center
Sign Up For More News
People Also Watch
GOOGL
Alphabet Inc
281.190
USD
-0.10%
RCI
Rogers Communications Inc
39.140
USD
-0.71%
GOOG
Alphabet Inc
281.820
USD
-0.03%
SCCD
Sachem Capital Corp
23.910
USD
-0.08%
SCCE
Sachem Capital Corp
22.760
USD
+0.22%
RWAYL
Runway Growth Finance Corp
25.180
USD
-0.16%
SANG
Sangoma Technologies Corp
5.190
USD
+3.39%
SAND
Sandstorm Gold Ltd (British Columbia)
0
USD
-6.44%
SA
Seabridge Gold Inc
23.830
USD
-0.13%
FAQ
What is Profound Medical Corp (PROF) stock price today?
The current price of PROF is 6.07 USD — it has decreased -0.82 % in the last trading day.
What is Profound Medical Corp (PROF)'s business?
What is the price predicton of PROF Stock?
What is Profound Medical Corp (PROF)'s revenue for the last quarter?
What is Profound Medical Corp (PROF)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Profound Medical Corp (PROF)'s fundamentals?
How many employees does Profound Medical Corp (PROF). have?